Top Story Today
The FDA Can Now Watch Clinical Trial Data Roll In Live
The FDA unveiled a framework for real-time clinical trial monitoring, and it's already working. AstraZeneca's Phase 2 lymphoma study is streaming safety and efficacy data to regulators via secure cloud as patients are treated. Amgen has a second proof-of-concept trial in setup. A broader pilot program launches this summer, with participant selection by August. For an industry that loses roughly $840,000 per day for every drug stuck in development limbo, compressing the gap between "trial complete" and "drug approved" from years to months could be transformative.
Why it matters: This lands alongside the FDA's recent shift to one-pivotal-trial approvals and signals a fundamental rethinking of how drugs move from testing to market. Early adopters building real-time data infrastructure could gain a massive speed advantage over competitors still shipping binders.
Read more →Deals & Strategy
Teva Drops $700M on a Rare New Tourette Drug
Only a handful of drugs have ever been approved for Tourette syndrome, with the last being aripiprazole in 2014. Teva just paid $700M upfront (up to $900M total) for Emalex Biosciences and its D1 receptor antagonist ecopipam, which cut relapse risk in half in a Phase 3 trial of 216 patients. NDA submission is planned for the second half of 2026, with Orphan Drug exclusivity providing a competitive moat.
Read more →GSK Bets Its Future on Becoming a Cancer Powerhouse
GSK's oncology sales surged 43% to 2 billion pounds in 2025, and new CEO Luke Miels is running five simultaneous Phase 3 trials for a single ADC drug called Mo-rez. The company famous for inhalers and HIV pills is now sprinting into one of pharma's most crowded markets, targeting 40 billion pounds in total sales by 2031.
Read more →Clinical & Regulatory
AstraZeneca's Two Biggest Cancer Bets Just Hit a Regulatory Wall
The FDA flagged serious concerns about both camizestrant (breast cancer) and Truqap (prostate cancer expansion) ahead of an April 30 advisory committee. Prediction markets give Truqap just 18% approval odds. The agency questions whether camizestrant's trial design proves anything, and whether Truqap's modest 19% risk reduction justifies adding side effects for mostly asymptomatic patients.
Read more →The Asthma Drug Class That Still Can't Catch a Break
FLAP inhibitors have never reached market, despite decades of attempts. AstraZeneca's atuliflapon is among the latest in the class to be tested in asthma. The recurring problem: these drugs crush their biochemical target perfectly but patients still don't get better.
Read more →Incyte's Vitiligo Cream Wins on Data, Faces a Pill-Shaped Threat
Opzelura posted strong Phase 3 vitiligo data and hit $678M in 2025 revenue (up 33%). But AbbVie filed Rinvoq, an oral pill, for the same disease in February. Incyte's safety advantage (a cream vs. a pill with a black box warning) protects localized cases, but widespread vitiligo patients may prefer swallowing one pill over applying cream everywhere.
Read more →Money & Markets
Erasca Hit a Home Run. The Stock Fell 47%.
Erasca's pan-RAS inhibitor posted a 62% response rate in lung cancer and 40% tumor shrinkage in pancreatic cancer, numbers analysts called spectacular. Then a treatment-related patient death, a patent infringement letter from Revolution Medicines, and questions about unconfirmed vs. confirmed response rates sent shares off a cliff in a single session.
Read more →Galapagos Ditched This Drug. Now It Raised $125 Million.
Coultreon Biopharma closed an oversubscribed $125M Series A (led by Sofinnova, Forbion, and Novo Holdings) for an oral immunology drug Galapagos transferred out as part of a strategic restructuring. The drug targets SIK3, acting like a thermostat that dials down inflammation while simultaneously boosting immune calming signals. Phase 2 data in psoriasis and ulcerative colitis expected in 2027.
Read more →